Non-sedating antihistamine injection formulations and methods of use thereof
View Patent ↗Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute allergic reactions including anaphylaxis with the compositions are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage forms. In other embodiments, the non-sedating or second and third generation antihistamine injectable formulations are therapeutically equivalent to diphenhydramine injectable formulations and/or are more effective than placebo. In other embodiments, a non-sedating antihistamine injectable composition is delivered by an autoinjector.
1. A method of treating acute urticaria associated with an acute allergic reaction comprising administering to an individual in an emergency situation an effective amount of an injectable composition comprising a non-sedating antihistamine, wherein the non-sedating antihistamine comprises racemic cetirizine or a salt thereof, wherein the injectable composition is in an aqueous solution having a pH of 3 to 9, and wherein administering comprises administration of 2 to 10 mg of racemic cetirizine.
2. The method of claim 1 , wherein the 90% confidence limits of a ratio of a logarithmic transformed geometric mean of AUC 0-INF for the injectable composition to a logarithmic transformed geometric mean of AUC 0-INF for a reference oral product of racemic cetirizine are 0.80 to 1.25.
3. The method of claim 1 , wherein the injectable composition further comprises a second active agent comprising ranitidine, cimetidine, epinephrine, methylprednisolone, prednisolone, or a combination thereof.
4. The method of claim 1 , wherein the injectable composition of cetirizine has a 90% confidence interval around the difference in the reduction of at least one symptom of acute urticaria associated with an acute allergic reaction including anaphylaxis to a reference injectable formulation, for the per protocol evaluable population, within about −30.00 to about +30.00, wherein the symptom is pruritus, number of urticaria areas, or urticaria areas.
5. The method of claim 4 , wherein the reference injectable formulation is a 12.5-150 mg dose of a 50 mg/mL diphenydramine injectable formulation.
6. The method of claim 1 , wherein the injectable composition of the non-sedating antihistamine is statistically superior (p<0.05) to a placebo in the reduction of at least one symptom of acute urticaria associated with an acute allergic reaction including anaphylaxis, wherein the symptom is pruritus, number of urticaria areas, or urticaria areas.
7. The method of claim 1 , wherein administering is intravenous injection.
8. The method of claim 1 , wherein administering is intramuscular injection.
9. The method of claim 1 , wherein the acute allergic reaction is anaphylaxis.